Abstract
Background Ketamine is a rapid-acting treatment for patients with treatment refractory depression (TRD), however treatment responses are often transient and ketamine’s antidepressant action lacks robust clinical durability. Little is known about which patient characteristics are associated with faster or more durable ketamine responses. Ketamine’s antidepressant mechanism is proposed to involve modulation of glutamatergic signaling leading to long term potentiation (LTP) and synaptogenesis, and these neuroplasticity pathways have been shown to be attenuated with older age. We therefore investigated the impact of patient age on the speed and durability of ketamine’s antidepressant effects in veterans receiving serial intravenous ketamine infusions for TRD.
Methods Beck Depression Inventory (BDI-II) scores from 49 veterans receiving six ketamine infusions (twice weekly) were examined from a retrospective case series. Percent change in BDI-II scores across the infusion series were assessed with respect to patient age using a mixed-linear model. Follow-up analyses examined the age x infusion number interaction effect at each assessment time point. To assess treatment durability, BDI-II change scores three weeks following the sixth infusion were correlated with age.
Results There was a significant age x infusion number interaction (F=3.01, p=.0274) across the six infusions. Beta estimates at each infusion showed a significant effect of age at infusion #4 (B=.88% +/-.29%, t=3.02, p=. 004) and a trend towards significance at infusion #5 (B=.62% +/-.31%, t=1.95, p=.057). There was no significant correlation between percent change in BDI-II and age at three-week follow-up.
Conclusions Older age is associated with an altered trajectory of antidepressant response across serial ketamine infusions, with a model-predicted difference of 8.8% less improvement in BDI-II score for each decade in age mid-way through the infusion course. In contrast, antidepressant durability at three-week follow-up was not related to age. These data suggest age is an important moderating factor of patient response to ketamine, and that differing mechanisms may underlie speed and durability of ketamine’s antidepressant activity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was not supported by any funding mechanisms.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCSF IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Drs. Fryer, Wallace, Mathalon and Marton are U.S. Government employees. The content is solely the responsibility of the authors and does not necessarily represent the views of the Department of Veterans Affairs.
Data Availability
Data available upon request of the corresponding author. This was not a clinical trial or prospective study so is not registered as a clinical trial. This was a retrospective case-series analysis.
